StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a research note published on Sunday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Price Performance
NASDAQ:EVOK opened at $4.14 on Friday. The firm has a 50 day simple moving average of $5.66 and a 200-day simple moving average of $6.23. The firm has a market cap of $35.55 million, a PE ratio of -2.26 and a beta of 0.38. Evoke Pharma has a 1-year low of $3.75 and a 1-year high of $18.60.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). The firm had revenue of $2.55 million during the quarter. Evoke Pharma had a negative net margin of 86.74% and a negative return on equity of 964.25%.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
See Also
- Five stocks we like better than Evoke Pharma
- Most Volatile Stocks, What Investors Need to Know
- 3 Small Cap Stocks That Insiders Are Buying
- What is a SEC Filing?
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
